ZFIN ID: ZDB-PUB-160204-3
Atrogin-1 Deficiency Leads to Myopathy and Heart Failure in Zebrafish
Bühler, A., Kustermann, M., Bummer, T., Rottbauer, W., Sandri, M., Just, S.
Date: 2016
Source: International Journal of Molecular Sciences   17(2): (Journal)
Registered Authors: Bühler, Anja, Just, Steffen, Rottbauer, Wolfgang
Keywords: Atrogin-1, autophagy, heart failure, myopathy, zebrafish
MeSH Terms:
  • Animals
  • Autophagy
  • F-Box Proteins/genetics
  • F-Box Proteins/metabolism
  • Heart Failure/genetics*
  • Heart Failure/metabolism
  • Muscle, Skeletal/metabolism
  • Muscle, Skeletal/ultrastructure
  • Muscular Diseases/genetics*
  • Muscular Diseases/metabolism
  • Myocytes, Cardiac/metabolism
  • Myocytes, Cardiac/ultrastructure
  • Zebrafish
  • Zebrafish Proteins/deficiency*
  • Zebrafish Proteins/genetics
  • Zebrafish Proteins/metabolism
PubMed: 26840306 Full text @ Int. J. Mol. Sci.
Orchestrated protein synthesis and degradation is fundamental for proper cell function. In muscle, impairment of proteostasis often leads to severe cellular defects finally interfering with contractile function. Here, we analyze for the first time the role of Atrogin-1, a muscle-specific E3 ubiquitin ligase known to be involved in the regulation of protein degradation via the ubiquitin proteasome and the autophagy/lysosome systems, in the in vivo model system zebrafish (Danio rerio). We found that targeted inactivation of zebrafish Atrogin-1 leads to progressive impairment of heart and skeletal muscle function and disruption of muscle structure without affecting early cardiogenesis and skeletal muscle development. Autophagy is severely impaired in Atrogin-1-deficient zebrafish embryos resulting in the disturbance of the cytoarchitecture of cardiomyocytes and skeletal muscle cells. These observations are consistent with molecular and ultrastructural findings in an Atrogin-1 knockout mouse and demonstrate that the zebrafish is a suitable vertebrate model to study the molecular mechanisms of Atrogin-1-mediated autophagic muscle pathologies and to screen for novel therapeutically active substances in high-throughput in vivo small compound screens (SCS).